Kanal Singh,Kevin Rubenstein,Viviane Callier,Katy Shaw-Saliba,Adam Rupert,Robin Dewar,Sylvain Laverdure,Helene Highbarger,Perrine Lallemand,Meei-Li Huang,Keith R Jerome,Reigran Sampoleo,Margaret G Mills,Alexander L Greninger,Kavita Juneja,Danielle Porter,Constance A Benson,Walla Dempsey,Hana M El Sahly,Chris Focht,Nikolaus Jilg,Catharine I Paules,Rekha R Rapaka,Timothy M Uyeki,H Clifford Lane,John Beigel,Lori E Dodd,Aneesh K Mehta,Nadine G Rouphael,Jessica J Traenkner,Valeria D Cantos,Ghina Alaaeddine,Barry S Zingman,Robert Grossberg,Paul F Riska,Elizabeth Hohmann,Mariam Torres-Soto,Nikolaus Jilg,Helen Y Chu,Anna Wald,Margaret Green,Annie Luetkemeyer,Pierre-Cedric B Crouch,Hannah Jang,Susan Kline,Joanne Billings,Brooke Noren,Diego Lopez de Castilla,Jason W Van Winkle,Francis X Riedo,Robert W Finberg,Jennifer P Wang,Mireya Wessolossky,Kerry Dierberg,Benjamin Eckhardt,Henry J Neumann,Victor Tapson,Jonathan Grein,Fayyaz Sutterwala,Lanny Hsieh,Alpesh N Amin,Thomas F Patterson,Heta Javeri,Trung Vu,Roger Paredes,Lourdes Mateu,Daniel A Sweeney,Constance A Benson,Farhana Ali,William R Short,Pablo Tebas,Jessie Torgersen,Giota Touloumi,Vicky Gioukari,David Chien Lye,Sean W X Ong,Norio Ohmagari,Ayako Mikami,Gerd Fätkenheuer,Jakob J Malin,Philipp Koehler,Andre C Kalil,LuAnn Larson,Angela Hewlett,Mark G Kortepeter,C Buddy Creech,Isaac Thomsen,Todd W Rice,Babafemi Taiwo,Karen Krueger,Stuart H Cohen,George R Thompson,Cameron Wolfe,Emmanuel B Walter,Maria Frank,Heather Young,Ann R Falsey,Angela R Branche,Paul Goepfert,Nathaniel Erdmann,Otto O Yang,Jenny Ahn,Anna Goodman,Blair Merrick,Richard M Novak,Andrea Wendrow,Henry Arguinchona,Christa Arguinchona,Sarah L George,Janice Tennant,Robert L Atmar,Hana M El Sahly,Jennifer Whitaker,D Ashley Price,Christopher J A Duncan,Simeon Metallidis,Theofilos Chrysanthidis,F McLellan,Myoung-don Oh,Wan Beom Park,Eu Suk Kim,Jongtak Jung,Justin R Ortiz,Karen L Kotloff,Brian Angus,Jack David Germain Seymour,Noreen A Hynes,Lauren M Sauer,Neera Ahuja,Kari Nadeau,Patrick E H Jackson,Taison D Bell,Anastasia Antoniadou,Konstantinos Protopapas,Richard T Davey,Jocelyn D Voell,Jose Muñoz,Montserrat Roldan,Ioannis Kalomenidis,Spyros G Zakynthinos,Catharine I Paules,Fiona McGill,Jane Minton,Nikolaos Koulouris,Zafeiria Barmparessou,Edwin Swiatlo,Kyle Widmer,Nikhil Huprikar,Anuradha Ganesan,Guillermo M Ruiz-Palacios,Alfredo Ponce de León,Sandra Rajme,Justino Regalado Pineda,José Arturo Martinez-Orozco,Mark Holodniy,Aarthi Chary,Timo Wolf,Christoph Stephan,Jan-Christian Wasmuth,Christoph Boesecke,Martin Llewelyn,Barbara Philips,Christopher J Colombo,Rhonda E Colombo,David A Lindholm,Katrin Mende,Tida Lee,Tahaniyat Lalani,Ryan C Maves,Gregory C Utz,Jens Lundgren,Marie Helleberg,Jan Gerstoft,Thomas Benfield,Tomas Jensen,Birgitte Lindegaard,Lothar Weise,Lene Knudsen,Isik Johansen,Lone W Madsen,Lars Østergaard,Nina Stærke,Henrik Nielsen,Timothy H Burgess,Michelle Green,Mat Makowski,Jennifer L Ferreira,Michael R Wierzbicki,Tyler Bonnett,Nikki Gettinger,Theresa Engel,Jing Wang,John H Beigel,Kay M Tomashek,Seema Nayak,Lori E Dodd,Walla Dempsey,Effie Nomicos,Marina Lee,Peter Wolff,Rhonda Pikaart-Tautges,Mohamed Elsafy,Robert Jurao,Hyung Koo,Michael Proschan,Dean Follmann,H Clifford Lane,the Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members

Abstract:Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to understanding antiviral efficacy in the multicenter ACTT-1 clinical trial that randomized patients to remdesivir or placebo. Longitudinal specimens collected during hospitalization from a substudy of 642 COVID-19 patients were measured for viral RNA (upper respiratory tract and plasma), viral nucleocapsid antigen (serum), and host immunologic markers. Associations with clinical outcomes and response to therapy were assessed. Higher baseline plasma viral loads were associated with poorer clinical outcomes, and decreases in viral RNA and antigen in blood but not the upper respiratory tract correlated with enhanced benefit from remdesivir. The treatment effect of remdesivir was most pronounced in patients with elevated baseline nucleocapsid antigen levels: the recovery rate ratio was 1.95 (95%CI 1.40-2.71) for levels >245 pg/ml vs 1.04 (95%CI 0.76-1.42) for levels < 245 pg/ml. Remdesivir also accelerated the rate of viral RNA and antigen clearance in blood, and patients whose blood levels decreased were more likely to recover and survive. Reductions in SARS-CoV-2 RNA and antigen levels in blood correlated with clinical benefit from antiviral therapy.

K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact

Personalized Assessment of Mortality Risk and Hospital Stay Duration in Hospitalized Patients with COVID-19 Treated with Remdesivir: A Machine Learning Approach

Difference in mortality rates in hospitalized COVID-19 patients identified by cytokine profile clustering using a machine learning approach: An outcome prediction alternative

Management of vulnerable patients hospitalized for COVID-19 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals

Does Remdesivir Lower COVID‐19 Mortality? A Subgroup Analysis of Hospitalized Adults Receiving Supplemental Oxygen

Remdesivir is associated with reduced mortality in patients hospitalized for COVID-19 not requiring supplemental oxygen

Predictors of mortality in hospitalised patients with COVID-19: a 1-year case-control study

Obtaining patient phenotypes in SARS-CoV-2 pneumonia, and their association with clinical severity and mortality

Clinical Phenotypes and Mortality Biomarkers: A Study Focused on COVID-19 Patients with Neurological Diseases in Intensive Care Units

Remdesivir-associated survival outcomes among immunocompromised patients hospitalized for COVID-19: real-world evidence from the Omicron dominant era

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis

Using Machine Learning As a Precision Medicine Approach for Remdesivir and Corticosteroids As COVID-19 Pharmacotherapies

Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis

Lower mortality risk associated with remdesivir + dexamethasone versus dexamethasone alone for the treatment of patients hospitalized for COVID-19

Machine Learning As a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

Diagnostic groups and short-term outcomes in suspected COVID-19 cases treated in an emergency department

Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19

Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry

SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5